Fig. 1: Ewing sarcoma (EWS) cells are sensitive to genetic and pharmacological inhibition of NAMPT with OT-82, an efficacious, on-target NAMPT inhibitor. | Oncogenesis

Fig. 1: Ewing sarcoma (EWS) cells are sensitive to genetic and pharmacological inhibition of NAMPT with OT-82, an efficacious, on-target NAMPT inhibitor.

From: Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

Fig. 1

a Immunoblot analysis of NAMPT expression in EWS cell lines. b Immunoblot analysis of NAMPT expression in TC71 72 h after NAMPT siRNA knockdown using multiple sequences. c Cellular viability, represented by percent confluence, 6 days after NAMPT siRNA transfection using multiple sequences in TC71. Quadruple asterisks (****) denote p < 0.0001 for one-way ANOVA with Dunnett’s multiple comparisons test, as compared to siNegative control. d IncuCyte live-cell analysis of EWS cell lines (TC71, TC32, and RDES) treated with 0.2–5 nM OT-82. e NAD+ and NADH concentrations in EWS cells treated with DMSO or 0.1–5 nM OT-82 for 72 h. Double asterisks (**) denote p < 0.01, quadruple asterisks (****) denote p < 0.0001 for one-way ANOVA with Dunnett’s multiple comparisons test. f IncuCyte live-cell analysis of EWS cell lines treated with DMSO or 10 nM OT-82 in the presence or absence of 1 mM NMN.

Back to article page